Anti-Human CD38 (HB-7) – Purified No Carrier Protein

Anti-Human CD38 (HB-7) – Purified No Carrier Protein

Product No.: C994

- -
- -
Clone
HB-7
Target
CD38
Formats AvailableView All
Product Type
Hybridoma Monoclonal Antibody
Alternate Names
HB7, T10, ADP-ribosyl cyclase
Isotype
Mouse IgG1 κ
Applications
FA
,
FC
,
IF
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Host Species
Mouse
Immunogen
BJAB Human B-cell Line
Product Concentration
≥1.0 mg/ml
Endotoxin Level
< 1.0 EU/mg as determined by the LAL method
Purity
≥90% monomer by analytical SEC and SDS-Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
State of Matter
Liquid
Storage and Handling
This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Regulatory Status
Research Use Only
Country of Origin
USA
Shipping
2-8°C Wet Ice
Additional Applications Reported In Literature ?
WB
IF
FA
FC
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
HB-7 activity is directed against human CD38.
Background
CD38 is a type II transmembrane glycoprotein that functions as an adhesion molecule with ectoenzymatic activities that contribute to intracellular calcium mobilization 1,2. Dysregulation is associated with a number of diseases, including HIV, autoimmune, type II diabetes mellitus, osteoporosis, and hematological malignancies such as multiple myeloma (MM) 1, a neoplasm characterized by clonal expansion of malignant plasma cells 2.

Because CD38 is strongly and uniformly expressed on myeloma cells, but has limited expression on normal cells, anti-CD38 antibody HB-7 was used to develop an antibody drug conjugate (ADC) capable of killing human myeloma and lymphoma cell lines 3. This ADC is composed of HB-7 conjugated to a chemically modified ricin molecule and is able to block protein synthesis in multiple myeloma cells and in normal bone marrow mononuclear cells.

HB-7 was developed by immunizing BALB/c mice with viable cells of the Human Burkitt lymphoma B cell line BJAB 4. The antibody binds to an epitope in the carboxyl terminus of CD38 between residues 273-285, which is also the site of enzyme activity 5. Binding is unaffected by the presence of NAD+ and does not influence CD38 catalytic activity 6.
Antigen Distribution
CD38 is expressed on plasma cells, other lymphoid and myeloid cell populations, natural killer cells, B cells, activated T cells, some peripheral regulatory T cells, monocytes, lymph node germinal center lymphoblasts, intrafollicular cells, dendritic cells, erythrocytes, platelets, committed stem cells, Purkinje cells, neurofibrillary tangles in the brain, epithelial cells in the prostate, β‐cells in the pancreas, retinal cells in the eye, and sarcolemma of smooth and striated muscle. CD38 can also be detected on early osteoclast progenitors but not on osteoblasts and mature osteoclasts. CD38 expression is very high and uniform on all malignant cells in multiple myeloma. While generally found on the plasma membrane, CD38 has also been detected in the cytosol or nucleus in brain, pancreatic acinar cells, smooth muscle, and osteoclasts.
Ligand/Receptor
CD31, Hyaluronic acid
NCBI Gene Bank ID
UniProt.org
Research Area
Cell Adhesion
.
Cell Biology
.
Immunology

References & Citations

1. van de Donk NW, Janmaat ML, Mutis T, et al. Immunol Rev. 270(1):95-112. 2016.
2. Morandi F, Horenstein AL, Costa F, et al. Front Immunol. 9:2722. 2018.
3. Goldmacher VS, Bourret LA, Levine BA, et al. Blood. 84(9):3017-3025. 1994.
4. Tedder TF, Clement LT, Cooper MD. Tissue Antigens24(3):140-149. 1984.
5. Hoshino S, Kukimoto I, Kontani K, et al. J Immunol.;158(2):741-747. 1997.
6. Berthelier V, Laboureau J, Boulla G, et al. Eur J Biochem. 267(10):3056-3064. 2000.
7. Collins A, Rothman N, Liu K, et al. JCI Insight. 2(5):e90063. 2017.
8. Caeser R, Di Re M, Krupka JA, et al. Nat Commun. 10(1):4543. 2019.
9. Imura Y, Ando M, Kondo T, et al. JCI Insight. 5(14):e136185. 2020.
10. Caeser R, Gao J, Di Re M, et al. Nat Protoc. 16(5):2499-2519. 2021.
11. Shukla S, Ying W, Gray F, et al. Nat Chem Biol. 17(7):784-793. 2021.
12. Nachmias B, Khan DH, Voisin V, et al. Leukemia. 36(5):1283-1295. 2022.
13. Volodarsky I, Shimoni S, Haberman D, J Cardiovasc Dev Dis. 10(1):2. 2022.
FA
Flow Cytometry
IF
General Western Blot Protocol

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.